Please login to the form below
gene-editing
This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.
Moderna and Life Edit partner to accelerate gene editing therapies
Moderna and Life Edit Therapeutics, an ElevateBio company, have entered into a strategic collaboration aimed at discovering and developing in vivo mRNA gene editing therapies for hard-to-treat diseases. ... The partnership will combine Life Edit's suite
Latest news
-
New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine
The results were published in a peer-reviewed paper in Nature. Patients diagnosed with untreatable cancers have been involved in a new experimental study exploring the potential of gene editing technology ... short palindromic repeats (CRISPR) technology,
-
ICR study raises possibility of predicting drug resistance in advance
The study, published in the journal Cancer Research, involved the use of the gene editing technology CRISPR to break or switch off each of 25, 000 genes in cancer cells treated ... and also led to increased activity of another gene called SMG1, which
-
Genentech and ArsenalBio join to identify successful T-cell oncology therapies
ArsenalBio’s engineering platform spans a range of cutting-edge technology, including high-throughput CRISPR-based gene editing, synthetic biology and computational biology, to create new synthetic biological programmes aimed at
-
Novartis and Precision BioSciences announce in vivo gene editing collaboration
Novartis and Precision BioSciences (Precision) have announced an in vivo gene editing research and development collaboration to develop potentially curative treatments for disorders including sickle cell disease (SCD) and beta thalassaemia.
-
AstraZeneca officially opens new R&D facility in UK
said. The Discovery Centre will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next-generation therapeutics, including nucleotide-based, gene-editing and cell
More from news
Approximately 10 fully matching, plus 59 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
Lastly, gene editing is a hugely promising area for new drug development in which DNA is inserted, deleted, modified or replaced in a genome. ... One of these adaptations relates to patient enrolment. Whereas previously CROs were able to draw on a
-
Alzheimer’s: the search for a cure
gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by biotech until the progress of companies
-
Novo Nordisk awakens its ‘Sleeping Beauty’
The next phases were to enrich the pipeline with acquisitions and partnerships, including a headline deal with blue-bird bio for next generation gene editing that could lead to a potential ... We also have a stem cell platform, gene editing, an exquisite
-
It started with a miss
There are huge implications for communications. Take gene editing, for example. ... We’re going to get to the point where treatments like gene therapies will be ubiquitous – so we need to set ourselves up for them now and embrace the ethical debate
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... These include pipeline gene-editing therapies from Sanofi and luspatercept from Celgene to name but a few, although
More from intelligence
Approximately 2 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “With his deep understanding of the gene-editing landscape and extensive
-
Marc Becker joins CRISPR Therapeutics
He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered with CRISPR Therapeutics to develop a gene-editing treatment for beta-thalassemia and sickle cell. ... The move marks a continuation in its
-
Rare Disease Day – looking to the future with hope
In addition to pharmaceutical company involvement, several advocacy groups are also driving clinical research and the development of technologies such as gene therapy, gene editing and antisense oligonucleotides. ... 2021), examined the diagnostic
-
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full ... potential of cell &gene
-
Gene Editing and Precision Medicine: The Future of Healthcare?
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine.
-
Spotlight interview: 15 minutes on medical and scientific writing
A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is
More from PMHub
Approximately 2 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
